| Description |
1 online resource. |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
Pharmacology-research, safety testing, and regulation |
|
Pharmacology-research, safety testing, and regulation series.
|
| Bibliography |
Includes bibliographical references and index. |
| Note |
Online resource; title from PDF title page (EBSCO, viewed February 17, 2015). |
| Contents |
ZOLEDRONIC ACID: CLINICAL USES, THERAPEUTIC EFFECTS AND PHARMACOKINETICS; ZOLEDRONIC ACID: CLINICAL USES, THERAPEUTIC EFFECTS AND PHARMACOKINETICS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Use of Zoledronic Acid in Men and Women with Low Bone Mass; Abstract; Zoledronic Acid, Low Bone Mass and Osteoporosis; Mechanism of Action; Pharmokinetics; Clinical Studies; Treatment of Post-Menopausal Osteoporosis; Men and Women with a Recent Low Trauma Hip Fracture; Imaging Studies; Extension Studies; Use in Women with Low Bone Mass; Osteoporosis in Men. |
|
Glucocorticoid-Induced OsteoporosisSpecial Populations; Secondary Osteoporosis in Children; Spinal Cord Injury; HIV; Frail Long Term Care Residents; Comparison of Different Agents; Combination Therapy; Adverse Events; Adherence, Compliance and Persistence; Conclusion; References; Chapter 2: Clinical and Experimental Evidences of Anti-Myeloma Activities of Zoledronic Acid; Abstract; Introduction; Myeloma Bone Disease; Bisphosphonates; Experimental Evidence of Anti-Cancer Activity by; Zoledronic Acid; Anti-Myeloma Activity of Zoledronic Acid; Myeloma Plasma Cells/Microenvironment Interactions. |
|
Zoledronate-Mediated AntiangiogenesisImmunomodulation by Zoledronate; Direct Antimyeloma Activity by Zoledronate; Clinical Evidence of Zoledronic; Acid Antimyeloma Activity; Conclusion; References; Chapter 3: The Use of Zoledronic Acid in Osteoarthritis: From Animal Models to Clinical Studies; Abstract; Abbreviations; Introduction; Methods; Search Strategy; Study Eligibility; Study Identification; Data Extraction and Outcome Measures; Data Analysis; Results; Data from Animal Models; Use of the Monoiodoacetate Model to Assess Efficacy of Zoledronic Acid. |
|
Zoledronic Acid Inhibits MIA-Induced Loss of Bone Mineral Density and PainMedial Meniscectomy Model of Osteoarthritis; Investigation of Zoledronic Acid Using the Chymopapain Model; Clinical Trials of Zoledronic Acid in People with OA; Use of Zoledronic Acid as Non-Operative Treatment for Knee Osteoarthritis; Use of Zoledronic Acid Pre-Operatively in Knee Osteoarthritis; Potential Side-Effects; Conclusion; Acknowledgment; References; Chapter 4: Treatment with Zoledronic Acid in Paget's Disease of Bone; Abstract; Introduction; Paget's Disease of Bone. |
|
Treatment of Paget's Disease of Bone: Objectives and IndicationsDosage Regimen and Treatment Recommendations with Zoledronic Acid in Paget's Disease of Bone; Efficacy of Treatment with Zoledronic Acid in the Control of Short-Term Bone Metabolism; Efficacy in Long-Term Bone Metabolism Control; Efficacy in Controlling Clinical Manifestations; Retreatment with Zoledronic Acid; Safety; Conclusion; References; Chapter 5: Bisphosphonates: Pharmacokinetics, Clinical Uses and Safety; Abstract; 1.2. Pharmacokinetics; 2. Therapeutic Activity and Clinical Uses; 3. Safety of Bishosphonates; Conclusion. |
| Summary |
Zoledronic acid is a third generation bisphosphonate which is administered intravenously once yearly at a dose of 5mg for multiple reasons including the treatment of post-menopausal women with osteoporosis to reduce the incidence of vertebral, hip and non-vertebral fractures and to increase bone mineral density (BMD), the prevention of clinical fractures after hip fracture in women and men, treatment of osteoporosis in men, prevention and treatment of glucocorticoid-induced osteoporosis (GIO), the prevention of post-menopausal osteoporosis (in the US) and the treatment of Paget's disease of th. |
| Subject |
Diphosphonates -- Therapeutic use.
|
|
Diphosphonates -- Pharmacokinetics.
|
|
Diphosphonates -- Emploi en thérapeutique.
|
|
Diphosphonates -- Pharmacocinétique.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Diphosphonates -- Therapeutic use
|
| Other Form: |
Print version: Carman, Ronald. Zoledronic Acid : Clinical Uses, Therapeutic Effects and Pharmacokinetics. Hauppauge : Nova Science Publishers, Inc., ©2014 9781633215252 |
| ISBN |
9781633215528 (electronic bk.) |
|
1633215520 (electronic bk.) |
|
9781633215252 |
| Standard No. |
GBVCP 815038534 |
|
AU@ 000056110198 |
|
